Title: Transcription profiling of human umbilical vein endothelial cells (HUVEC) treated with thrombin and leukotriene D4 (LTD4) with ethanol controls to delineate
Organism(s): Homo sapiens
Description: Cysteinyl leukotrienes (cysLT), i.e. LTC4, LTD4, and LTE4, are lipid mediators derived from the 5-lipoxygenase pathway. The cysLT receptors cysLT1-R and cysLT2-R are expressed on different target cells and mediate inflammatory reactions in tissue- and LT-R-specific ways. Though endothelial cells (ECs) predominantly express cysLT2-Rs, their role in vascular biology remains to be defined. To delineate cysLT2-R's action, we stimulated human umbilical vein EC with 100 nM LTD4 for 60 min, determined gene signatures by microarrays, and characterized the resulting EC phenotypes. As controls, we compared LTD4-induced genes with those induced by 10 nM thrombin, a prototype vasoactive activator of EC that binds to protease-activated receptor 1 (PAR-1). Following application of stringent filters 37 LTD4-upregulated genes were identified (> 2.5fold stimulation). Surprisingly, most of the LTD4-regulated genes were also induced by thrombin and expression of cysLT2-R- and PAR-1-regulated genes strongly correlated (Pearson correlation coefficient: r = 0.90). Moreover, LTD4 + thrombin, when added together, augmented expression of LTD4- or thrombin-stimulated genes (Wilcoxon signed rank test: p < 0.01). Prominently induced genes that may play roles in vascular injury were studied in detail: Early growth response (EGR) and nuclear receptor subfamily 4 group A; E-selectin; CXC ligand 2; interleukin 8 (IL-8); a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 1 (ADAMTS-1); and tissue factor (TF). Transcripts of these genes peaked at approximately 60 min, were unaffected by the cysLT1-R antagonist montelukast, and were superinduced by cycloheximide. The EC phenotype was markedly altered: LTD4 induced de novo synthesis of EGR1 protein and EGR1 localized in the nucleus in LTD4-stimulated cells; LTD4 upregulated IL-8 formation and secretion; and LTD4 raised TF protein and TF-dependent EC pro-coagulant activity. These data show that cysLT2-R activation results in a pro-inflammatory EC phenotype through activation of immediate-early genes that resemble those induced by PAR-1. As LTD4 and thrombin are formed concomitantly during vascular injury and pro-thrombotic states, cysLT2-R and PAR-1 may collaborate in vivo to mediate vascular injury and repair. Experiment Overall Design: HUVEC in passage 1 were cultured in serum-free EC medium until cells reached confluency. HUVEC were stimulated by 100 nM LTD4 (n = 4) or 10 nM thrombin (n = 4) or both agonists concomitantly (n = 3). The immediate-early gene programs of these experimental groups were identified at 60 minutes. In addition, one HUVEC preparation was stimulated with 100 nM LTD4 for 6 h and 24 h.
Design(s): time_series_design, compound_treatment_design, co-expression_design, transcription profiling by array
Experimental factor(s):
5 recorded
1 1 h 24 h 6 24
5 recorded
control LTD4 control condition thrombin LTD4/thrombin
4 recorded
100 nM 0.05% 10nM/0.05% 100 nM/10 nM
Publication(s): Barbara Uzonyi, Katharina Lötzer, Steffen Jahn, Cornelia Kramer, Markus Hildner, Ellen Bretschneider, Dörte Radke, Michael Beer, Rüdiger Vollandt, Jilly F Evans, Colin D Funk, Andreas J R Habenicht
Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. PubMed:16606835

Sample attribute(s):
1 recorded
HUVEC cell
Material Type
2 recorded
synthetic_RNA total_RNA
100 nM LTD4 treatment
1 recorded
leukotriene D4
10 nM thrombin treatment
1 recorded
zero-point-zero-five per cent ethanol in medium
1 recorded
duration of stimulation
3 recorded
1 hour 24 hour 6 hour
1 recorded
1 recorded
Homo sapiens
Contact(s): Andreas Johann Richard Habenicht
Release Date: 10/27/2007
Submission Date:
Metadata Downloads Download Study Metadata as ISAtabDownload Study Metadata as ISAtab
Assay Downloads
transcription profiling using DNA microarray
21 assays